New study confirms Actos bladder cancer link

by Heygood Orr and Pearson

Preliminary results from a new study of patients taking the diabetes medication Actos have confirmed a link between the use of the drug and an increased risk of bladder cancer. The study—which is analyzing incidents of bladder cancer in diabetes patients who are insured with Kaiser Permanente Northern California—is scheduled to continue until December 2013.

According to preliminary results from the study, type II diabetes patients who are prescribed Actos are more likely to develop bladder cancer than patients who are treated with other diabetes drugs. Nearly 200,000 diabetes patients were tracked as part of the study, including more than 33,000 Actos users.

Researchers also found that the increased risk of bladder cancer caused by the use of Actos became even greater the longer patients were treated with the drug. Patients who took Actos for the longest duration in the study were more than 60% more likely to be diagnosed with bladder cancer than patients who took the drug for the shortest duration.

Concerns about the link between Actos and bladder cancer first arose in June 2011, when a French study found that Actos users were more likely to be diagnosed with disease. In response to this report on the Actos bladder cancer link, health officials in France and Germany withdrew the drug from sale in those countries, citing the health risks of the diabetes drug.

For more information about Actos bladder cancer and to learn more about filing an Actos lawsuit, contact the lawyers at Heygood, Orr & Pearson by calling toll-free at 1-877-446-9001 or by completing the free contact form located on this page.